Potential Growth Opportunities in the Global Biologics Contract Development and Manufacturing Landscape
Asset co-development with clinical-stage biopharmaceutical companies and disruptive technologies present future growth potential
Click image to view it in full size
The year 2020 witnessed a global shortage of pharmaceuticals raw materials due to supply deficits that were caused by the COVID-19 pandemic. As the year progressed, the situation worsened as many governments banned the raw materials exports to ensure adequate vaccine supplies for their respective nations. But with the emergency approvals of successful vaccines, big pharma companies including Moderna, AstraZeneca, and Johnson & Johnson were in need of manufacturing partners with vaccine production expertise and capabilities. Bio-CDMOs have played a key role in enabling the manufacturing and delivery of the breakthrough vaccines to various regions across the world.
This study presents the key growth avenues and growth opportunities in the Bio-CDMO market market by analyzing the evolution and shifts that are taking place both in the business models and the strategic approach being adopted by the pharmaceutical sponsors. In addition, the study also outlines several interesting insights in the competitive landscape segment of the global Bio-CDMO market.
Take your first step towards achieving growth-centric solutions with our
Growth Pipeline Dialog™. Speak to our industry experts in a complimentary open discussion that will spark innovative thinking and growth opportunities that will benefit your organization.